中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (3): 199-201.doi: 10.12144/zgmfskin202403199

• 病例报告 • 上一篇    下一篇

司库奇尤单抗治疗重度斑块状银屑病发生大疱性类天疱疮一例

常佳玉1,2,齐妙1,2,王一民1,2,李永喜1,史同新1   

  1. 1青岛市市立医院皮肤科，山东青岛，266011；2大连医科大学临床医学院，辽宁大连，116000
  • 出版日期:2024-03-15 发布日期:2024-02-28

Bullous pemphigoid occurred in a patient with severe plaque psoriasis treated with secukinumab: a case report

CHANG Jiayu1,2, QI Miao1,2, WANG Yimin1,2, LI Yongxi1, SHI Tongxin1   

  1. 1 Department of Dermatology, Qingdao Municipal Hospital, Qingdao 266011, China;2 Clinical College of Dalian Medical University, Dalian 116000, China
  • Online:2024-03-15 Published:2024-02-28

PDF (PC)

198

摘要： 司库奇尤单抗是一种靶向白介素-17A（IL-17A）的重组全人源单克隆抗体，目前被批准用于治疗中重度银屑病，虽然其表现出良好的安全性和耐受性，但国际上仍有报道关于在使用司库奇尤单抗的过程中诱发多种自身免疫性疾病的案例，如系统性红斑狼疮、大疱性类天疱疮等。本文报道一例在应用司库奇尤单抗治疗重度斑块状银屑病的过程中发生大疱性类天疱疮的病例。

关键词: 司库奇尤单抗, 大疱性类天疱疮, 银屑病

Abstract: Secukinumab is a recombinant human monoclonal antibody targeting interleukin-17A (IL-17A), currently approved for the treatment of moderate to severe psoriasis. Although it exhibits good safety and tolerance, there are still reports of inducing multiple autoimmune diseases during the use of secukinumab, such as systemic lupus erythematosus and bullous pemphigoid. This article reports a case of bullous pemphigoid that occurred during the treatment of severe plaque psoriasis with secukinumab.

Key words: secukinumab, bullous pemphigoid, psoriasis